Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-07-19
2011-07-19
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S138100, C424S133100, C424S155100, C424S135100, C530S387100, C530S388220, C530S388800, C530S350000, C530S387700, C530S387300, C514S001100, C514S008900, C514S018900, C514S019300, C514S021200
Reexamination Certificate
active
07981421
ABSTRACT:
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
REFERENCES:
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6294546 (2001-09-01), Rosen et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6534061 (2003-03-01), Goddard et al.
patent: 6635482 (2003-10-01), Yu et al.
patent: 6872568 (2005-03-01), Ni et al.
patent: 6965023 (2005-11-01), Reed et al.
patent: 7105640 (2006-09-01), Desnoyers et al.
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2003/0228309 (2003-12-01), Salcedo et al.
patent: 0125023 (1984-11-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/03992 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12963 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
patent: WO 00/66156 (2000-11-01), None
patent: WO 00/67793 (2000-11-01), None
patent: WO 00/73349 (2000-12-01), None
patent: WO 00/75191 (2000-12-01), None
patent: WO 01/19861 (2001-03-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 01/83560 (2001-11-01), None
patent: WO 02/79377 (2002-10-01), None
Adams et al., “Structural and functional analysis of the interaction between agonist monoclonal antibody Apomab and the proapoptotic receptor DR5”Cell Death Diff. 15:751-761 (2008).
Arai et al., “Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas” Cancer Letters 133(2):197-204 (1998).
Ashkenzai et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand” J. Clin. Invest. 104:155-62 (1999).
Bendele et al., “Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats” Clin Exp. Rheumatol. 17(5):553-560 (1999).
Berckmans et al., “Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism” Arthritis Rheum. 46(11):2857-66(2002).
Bodmer et al., “Trail receptor-2 signals apoptosis through FADD and caspase-8” Nat. Cell Biol. 2:241-3 (2000).
Bonavida et al., “Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review)” Int. J. Oncol. 15:793-802 (1999).
Bretz et al., “Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells”Cell Death and Diff. 9:274-286 (2002).
Buchsbaum et al., “Treatment of human breast cancer xenografts with monoclonal antibody against DR5 with or without chemotherapy inhibits tumor growth in nude mice”Proceedings of the Annual Meeting of the American Association for Cancer Research43:1005-6 (Mar. 2002) (Abstract).
Buchsbaum et al., “Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model”Clinical Cancer Research9(10 Pt. 1):3731-3741 (2003).
Chaudhary et al., “Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NFκB pathway” Immunity 7(6):821-30 (1997).
Chinnaiyan et al., “Combined effect of tumor necrosis-factor related apotosis-inducing ligand and ionizing radiation in breast cancer therapy” PNAS 97(4):1754-9 (2000).
Choy et al., “Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-t receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial” Arthritis Rheum. 46(12):3143-50 (2002).
Chuntharapai et al., “Isotype-Dependent Inhibition of Tumor Growth in Vivo by Monoclonal Antibodies to Death Receptor 4” J. Immunol. 166:4891-4898 (2001).
Ciranni et al., “The 'Braids Lady' of Arezzo: a case of rheumatoid arthritis, in a 16th century mummy” Clin. Exp. Rheumatol. 20(6):745-52 (2002).
Clarke et al., “Reovirus-Induced Apoptosis Is Mediated by TRAIL” J. Virol. 74(17): 8135-8139 (2000).
Czuczman et al., “Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy” J. Clin. Oncol. 17(1):268-76 (1999).
Degli-Esposti et al., “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family” J. Exp. Med. 186(7):1165-1170 (1997).
Degli-Eposti et al., “The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL mediated apoptosis, yet retains an incomplete death domain” Immunity 7:813-20 (1997).
Desrosier et al., “Treatment with gemcitabine and Tra-8 anti-death-receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo”Journal of Gastrointestinal Surgery10(9):1291-1300 (2006).
Emery et al., “Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL” J. Biol. Chem. 273(23):14363-7 (1998).
Fanger et al., “Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)” J. Exp. Med. 190(8):1155-64 (1999).
Foote and Winter, “Antibody framework residues affecting the conformation of the hypervariable loops”J. Mol. Biol.224(2):487-99 (1992).
Fujisawa et al., “Therapeutic Effect of the Anti-Fas Antibody on Arthritis in HTLV-I tax Transgenic Mice” J. Clin. Invest. 98(2): 271-278 (1996).
Gazda et al., “Gene expression changes in bone marrow cells from Diamond-Backfan anemia patients” Blood 104(11), pt. 1:206A-207A (2004).
Gibson, et al., “Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL” Molecular and Cellular Biology 20(1):205-212 (2000).
Griffith et al. “Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies,” J. Immunol. 162: 2597-2605 (1999).
Herr et al., “JNK/SAPK activity contributes to TRAIL-induced apoptosis” Cell Death Differ. 6:130-5 (1999).
Ichikawa et al. “Tumoricidal activity of a novel anti-human DR5 monoclonal. antibody without hepatocyte cytotoxicity,” Nature Med. 7(8): 954-960 (2001).
Ichikawa et al., “Tumoricidal activity in the absence of hepatocyte cytotoxicity of a novel antihuman DR5 monoclonal antibody”FASEB Journal15(5):a1198 (2001).
Ichikawa et al., “TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis”J. Immunol. 171(2):1061-1069 (2003).
Jeremias et al., “TRAIL induces apoptosis and activation of NF-kappaB” Eur. Cytokine Netw. 9:687-8 (1998).
Jo et al., “Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand” Nat. Med. 6:564-7 (2000).
Keane et al. “Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines” Cancer Res. 59:734-741(1999).
Kischkel et al., “Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5” Immunity 12:611-20 (2000).
Kuang et al., “FADD is required for DR4- and DR5-m
Buchsbaum Donald J.
Ichikawa Kimihisa
Kimberly Robert P.
Koopman William J.
LoBuglio Albert F.
Kaufman Claire
McKeon Meunier Carlin Curfman
Spector Lorraine
The UAB Research Foundation
LandOfFree
Combinations of antibodies selective for DR5 and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of antibodies selective for DR5 and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of antibodies selective for DR5 and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663980